Livforsakringsbolaget Skandia Omsesidigt Raises Stock Holdings in Danaher Co. (NYSE:DHR)

Livforsakringsbolaget Skandia Omsesidigt grew its holdings in shares of Danaher Co. (NYSE:DHR) by 323.7% during the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 5,907 shares of the conglomerate’s stock after buying an additional 4,513 shares during the period. Livforsakringsbolaget Skandia Omsesidigt’s holdings in Danaher were worth $1,643,000 as of its most recent SEC filing.

Other large investors also recently bought and sold shares of the company. Tsfg LLC grew its stake in shares of Danaher by 733.3% in the 1st quarter. Tsfg LLC now owns 100 shares of the conglomerate’s stock worth $25,000 after buying an additional 88 shares during the last quarter. nVerses Capital LLC purchased a new stake in shares of Danaher in the second quarter worth $25,000. CarsonAllaria Wealth Management Ltd. bought a new position in shares of Danaher during the second quarter valued at $25,000. Redmont Wealth Advisors LLC purchased a new position in shares of Danaher in the 1st quarter worth about $30,000. Finally, Richardson Financial Services Inc. bought a new position in Danaher in the 4th quarter worth about $42,000. 79.05% of the stock is owned by hedge funds and other institutional investors.

Danaher Price Performance

Shares of NYSE:DHR opened at $270.33 on Friday. The firm’s 50 day simple moving average is $270.31 and its two-hundred day simple moving average is $259.20. The company has a debt-to-equity ratio of 0.33, a current ratio of 1.43 and a quick ratio of 1.04. The company has a market capitalization of $200.23 billion, a P/E ratio of 45.82, a P/E/G ratio of 4.49 and a beta of 0.83. Danaher Co. has a 1-year low of $182.09 and a 1-year high of $281.70.

Danaher (NYSE:DHR) last released its earnings results on Tuesday, July 23rd. The conglomerate reported $1.72 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.57 by $0.15. Danaher had a return on equity of 11.06% and a net margin of 16.94%. The firm had revenue of $5.74 billion during the quarter, compared to analysts’ expectations of $5.59 billion. During the same quarter last year, the business posted $2.05 earnings per share. The firm’s revenue was down 2.9% on a year-over-year basis. Research analysts expect that Danaher Co. will post 7.59 EPS for the current fiscal year.

Danaher Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Friday, October 25th. Investors of record on Friday, September 27th will be given a dividend of $0.27 per share. The ex-dividend date is Friday, September 27th. This represents a $1.08 dividend on an annualized basis and a dividend yield of 0.40%. Danaher’s dividend payout ratio is 18.31%.

Analysts Set New Price Targets

Several equities research analysts recently weighed in on the stock. Robert W. Baird raised their price target on shares of Danaher from $271.00 to $278.00 and gave the company an “outperform” rating in a research report on Wednesday, July 24th. TD Cowen boosted their target price on Danaher from $290.00 to $310.00 and gave the stock a “buy” rating in a research report on Wednesday, July 24th. Wells Fargo & Company began coverage on shares of Danaher in a report on Tuesday, August 27th. They set an “equal weight” rating and a $280.00 price target on the stock. Bank of America increased their price objective on shares of Danaher from $270.00 to $275.00 and gave the company a “neutral” rating in a research report on Wednesday, July 24th. Finally, Royal Bank of Canada reiterated an “outperform” rating and set a $300.00 target price on shares of Danaher in a research note on Friday, September 6th. Seven analysts have rated the stock with a hold rating and twelve have assigned a buy rating to the stock. According to MarketBeat, Danaher presently has an average rating of “Moderate Buy” and an average price target of $282.12.

Insider Buying and Selling at Danaher

In other news, SVP Brian W. Ellis sold 9,600 shares of the firm’s stock in a transaction dated Thursday, July 25th. The stock was sold at an average price of $275.16, for a total transaction of $2,641,536.00. Following the completion of the transaction, the senior vice president now owns 20,230 shares in the company, valued at $5,566,486.80. This trade represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. In other news, SVP Georgeann Couchara sold 952 shares of the stock in a transaction that occurred on Monday, August 26th. The stock was sold at an average price of $268.37, for a total transaction of $255,488.24. Following the completion of the transaction, the senior vice president now directly owns 4,212 shares in the company, valued at approximately $1,130,374.44. This represents a 0.00 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, SVP Brian W. Ellis sold 9,600 shares of the business’s stock in a transaction on Thursday, July 25th. The stock was sold at an average price of $275.16, for a total transaction of $2,641,536.00. Following the completion of the sale, the senior vice president now owns 20,230 shares in the company, valued at $5,566,486.80. This represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 39,659 shares of company stock worth $11,042,433. Insiders own 11.10% of the company’s stock.

About Danaher

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.